Nventa Develops Proprietary Vaccin...( Potent Adjuvant is a Toll-L...),Health

Potent Adjuvant is a Toll-Like Receptor 3 (TLR3) Agonist

SAN DIEGO, June 18 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today announced that the company has developed a proprietary vaccine adjuvant, Poly IC-Poly Arginine (Poly-ICR), that has broad potential for use in both therapeutic and prophylactic vaccines.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

Poly-ICR is a Toll-like Receptor 3 (TLR3) agonist that when combined with a disease-specific antigen can induce both cytotoxic (T-cell) and antibody (B-cell) immune responses against that antigen. Cytotoxic T-cells, also referred to as CD8 T-cells, are required to target and eliminate pathogen-infected or cancerous cells. Antibodies, or B-cells, are required to protect against an infection caused by a pathogen. Poly-ICR, therefore, has potential utility in both the therapeutic and prophylactic areas of immunotherapy and vaccine development. This novel and potent immunomodulator works with the immune system to induce dendritic cell maturation, along with a broad range of inflammatory cytokines and chemokines, to facilitate the prevention and treatment of infectious diseases or cancer.

Data generated using Poly-ICR, in combination with a tumor-associated antigen, have demonstrated that the addition of the adjuvant potently increases the antigen-specific CD8 T-cell levels, while both inducing regression of tumors and preventing tumor growth in mouse models. Poly-ICR is differentiated from other Poly IC compositions by its high stability and potency in human sera, as well as its consistency in physical-chemical properties. Nventa has successfully manufactured research and development lots of Poly-ICR and expects that its current manufacturing process can be used to produce future cGMP material.

"We believe that Poly-ICR will add tremendous
'/>"/>